CU20210044A7 - Pirazoles como moduladores de hemoglobina - Google Patents

Pirazoles como moduladores de hemoglobina

Info

Publication number
CU20210044A7
CU20210044A7 CU2021000044A CU20210044A CU20210044A7 CU 20210044 A7 CU20210044 A7 CU 20210044A7 CU 2021000044 A CU2021000044 A CU 2021000044A CU 20210044 A CU20210044 A CU 20210044A CU 20210044 A7 CU20210044 A7 CU 20210044A7
Authority
CU
Cuba
Prior art keywords
modulators
pyrazole
tautomers
hbs
formula
Prior art date
Application number
CU2021000044A
Other languages
English (en)
Inventor
Shawn Cabral
Agustin Casimiro-Garcia
Ming Zhu Chen
Chulho Choi
Robert Lee Dow
Olugbeminiyi Omezia Fadeyi
Ariamala Gopalsamy
David Hepworth
Jayasankar Jasti
Lyn Howard Jones
Arjun Venkat Narayanan
Mihir Dineshkumar Parikh
David Walter Piotrowski
Lee Richard Roberts
Robinson, Jr
Hatice Gizem Yayla
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU20210044A7 publication Critical patent/CU20210044A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La invención se relaciona con derivados de pirazol.</p> <p>Más particularmente la invención se relaciona con moduladores de HbS de la Fórmula (I)</p> <p>Espacio para la fórmula.</p> <p>o tautómeros de los mismos, o sales farmacéuticamente aceptables de los moduladores o tautómeros de los mismos, en donde X, Y, R² y R³ son como se definen en la descripción.</p> <p>Los moduladores de HbS son potencialmente útiles en el tratamiento de un amplio margen de trastornos, que incluyen enfermedad de células falciformes (SCD).</p>
CU2021000044A 2018-11-29 2019-11-26 Pirazoles como moduladores de hemoglobina CU20210044A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772815P 2018-11-29 2018-11-29
US201962915784P 2019-10-16 2019-10-16
PCT/IB2019/060171 WO2020109994A1 (en) 2018-11-29 2019-11-26 Pyrazoles as modulators of hemoglobin

Publications (1)

Publication Number Publication Date
CU20210044A7 true CU20210044A7 (es) 2022-01-13

Family

ID=68807213

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000044A CU20210044A7 (es) 2018-11-29 2019-11-26 Pirazoles como moduladores de hemoglobina

Country Status (22)

Country Link
US (3) US11014908B2 (es)
EP (1) EP3886984A1 (es)
JP (1) JP2022510628A (es)
KR (1) KR20210097161A (es)
CN (1) CN113329789A (es)
AU (1) AU2019387290A1 (es)
BR (1) BR112021009057A2 (es)
CA (1) CA3121139A1 (es)
CO (1) CO2021006924A2 (es)
CR (1) CR20210284A (es)
CU (1) CU20210044A7 (es)
DO (1) DOP2021000103A (es)
EC (1) ECSP21037191A (es)
IL (1) IL283408A (es)
MA (1) MA54283A (es)
MX (1) MX2021006095A (es)
PE (1) PE20211592A1 (es)
PH (1) PH12021551035A1 (es)
SG (1) SG11202104585YA (es)
TW (2) TWI736037B (es)
UY (1) UY38488A (es)
WO (1) WO2020109994A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20210044A7 (es) * 2018-11-29 2022-01-13 Pfizer Pirazoles como moduladores de hemoglobina
PE20221902A1 (es) 2020-01-24 2022-12-21 Pfizer Anticuerpos anti-e-selectina, composiciones y metodos de uso
CN112079774A (zh) * 2020-10-17 2020-12-15 甘肃天后光学科技有限公司 软性隐形眼镜用蓝光吸收剂、其制备方法及应用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US8039674B2 (en) 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
JP2007176799A (ja) 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2011015524A2 (en) 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
AR082985A1 (es) 2010-09-14 2013-01-23 Exelixis Inc INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2811129T3 (es) * 2011-12-28 2021-03-10 Global Blood Therapeutics Inc Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2864707T3 (es) 2013-03-15 2021-10-14 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
JP6401772B2 (ja) 2013-03-15 2018-10-10 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20140271591A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9248199B2 (en) * 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
EP3157904B1 (en) 2014-06-20 2020-11-18 Institut Pasteur Korea Anti-infective compounds
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
JP6554547B2 (ja) 2014-11-03 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤
HRP20230271T1 (hr) 2014-11-16 2023-06-09 Array Biopharma, Inc. Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogen sulfata
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3472150A1 (en) 2016-06-17 2019-04-24 Fronthera U.S. Pharmaceuticals LLC Hemoglobin modifier compounds and uses thereof
US11001559B2 (en) 2016-08-15 2021-05-11 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
CU20210044A7 (es) * 2018-11-29 2022-01-13 Pfizer Pirazoles como moduladores de hemoglobina

Also Published As

Publication number Publication date
SG11202104585YA (en) 2021-06-29
TW202033513A (zh) 2020-09-16
WO2020109994A1 (en) 2020-06-04
AU2019387290A1 (en) 2021-05-27
CR20210284A (es) 2021-07-09
TW202140452A (zh) 2021-11-01
CO2021006924A2 (es) 2021-06-10
US20200172512A1 (en) 2020-06-04
EP3886984A1 (en) 2021-10-06
CA3121139A1 (en) 2020-06-04
MA54283A (fr) 2022-03-09
US11702405B2 (en) 2023-07-18
PH12021551035A1 (en) 2021-12-06
TWI736037B (zh) 2021-08-11
KR20210097161A (ko) 2021-08-06
US20220348555A1 (en) 2022-11-03
BR112021009057A2 (pt) 2021-08-10
US11014908B2 (en) 2021-05-25
JP2022510628A (ja) 2022-01-27
DOP2021000103A (es) 2021-07-30
ECSP21037191A (es) 2021-06-30
IL283408A (en) 2021-07-29
CN113329789A (zh) 2021-08-31
UY38488A (es) 2020-06-30
PE20211592A1 (es) 2021-08-18
US20230382892A1 (en) 2023-11-30
MX2021006095A (es) 2021-07-06

Similar Documents

Publication Publication Date Title
UY38448A (es) Compuestos de azol-amida pesticidamente activos
CU20210044A7 (es) Pirazoles como moduladores de hemoglobina
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
UY37900A (es) Nuevos derivados de rapamicina
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
PA8680701A1 (es) Derivados de oxindol
CO6612228A2 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
CO6270311A2 (es) Derivados bis-(sulfonilamino) en terapia 066
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CU20110078A7 (es) Compuestos de carbazol
UY31651A1 (es) Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
UY36073A (es) ?2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS?.
CR20110680A (es) Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton